Table 2. Selected current clinical trials of immunotherapy for locally advanced lung cancer.
Study | Drug | Trial Phase | Treatment Arm(s) | Enrollment (actual or planned) | Primary Endpoint |
---|---|---|---|---|---|
NCT02434081 (NICOLAS) | Nivolumab | 2 | CRT +/– concurrent Nivolumab | 94 | Grade 3+ pneumonitis |
NCT03519971 | Durvalumab | 3 | CRT +/– concurrent Durvalumab | 328 | PFS and ORR |
CRT, chemoradiation therapy; PFS, progression-free survival; ORR, objective response rate.